Expanded Access Protocol (EAP) For Patients Receiving Lisocabtagene Maraleucel That Is Nonconforming For Commercial Release

Grants and Contracts Details

StatusActive
Effective start/end date1/29/21 → 9/18/26

Funding

  • Celgene: $44,786.00